227 related articles for article (PubMed ID: 23241501)
1. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Chaudhary UB; Verma N; Keane T; Gudena V
Am J Clin Oncol; 2014 Apr; 37(2):188-93. PubMed ID: 23241501
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Endlicher E; Troppmann M; Kullmann A; Golder S; Herold T; Herfarth H; Grossmann J; Schlottmann K; Kullmann F
Oncology; 2007; 72(5-6):279-84. PubMed ID: 18187949
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Boukovinas I; Androulakis N; Kentepozidis N; Polyzos A; Papakotoulas P; Ziras N; Kotsakis A; Vardakis N; Karampeazis A; Markos V; Kostakopoulos A; Constantinides CA; Samonis G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2012 Feb; 69(2):351-6. PubMed ID: 21748359
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II.
Neri B; Doni L; Fulignati C; Gemelli MT; Turrini M; Di Cello V; Dominici A; Mottola A; Raugei A; Ponchietti R; Cini G
Anticancer Res; 2002; 22(5):2981-4. PubMed ID: 12530029
[TBL] [Abstract][Full Text] [Related]
16. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
[TBL] [Abstract][Full Text] [Related]
17. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
18. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
